ISLAMABAD: Shifa International Hospital (SIH) on Thursday successfully completed the first-ever SARS-CoV-2 Vaccine Trial (Phase III), commonly known as the Casino-Bio Trial in Pakistan to defeat Covid-19.

Dr Ejaz Khan, who is the principal investigator of this trial at the SIH, briefed the audience at the closing ceremony about the journey, benefits, and outcomes of the trial.

He termed the trial one of its kind with a single-dose vaccine against COVID-19 and a success as, only after five months, the vaccine was approved by the Drug Regulatory Authority of Pakistan (DRAP) and made available for the public in Pakistan which helped in saving thousands of lives.

He added that Pakistan soon started its production at the National Institute of Health (NIH) under the product name of PakVAc and was available for distribution as well.

Dr Ejaz acknowledged all the stakeholders, including brave volunteers of the trial, the NIH, research staff, the Cansino sponsor, other institutions, and the SIH’s administration which always encouraged and supported the research team during the trial in every possible way.

SIH CEO Dr Manzoor Hul Haq Qazi lauded the efforts of the research team who had successfully conducted the vaccine trials in the Shifa trial centre.

Dr Qazi, and Shifa Tameer-e-Millat University Vice Chancellor Dr Muhammad Iqbal Khan were one of the first few individuals who had volunteered for the trial at the SIH in the beginning.

  • APP

Leave a Reply

Your email address will not be published. Required fields are marked *

Translate »